These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1000 related items for PubMed ID: 25121186

  • 21. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T, Marcellin P.
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [Abstract] [Full Text] [Related]

  • 22. Peg-interfon alpha-2a and low-dose ribavirin for treatment of hepatitis C virus infection in patients with sickle-cell anemia in Saudi Arabia.
    Agha A, Chakik R, Abdulhadi Ali MM, Alsaudi D, Sammito G, Giannini EG.
    Ann Saudi Med; 2013 Jan; 33(6):610-3. PubMed ID: 24413867
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [Abstract] [Full Text] [Related]

  • 24. Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis.
    Soresi M, Tripi S, Franco V, Giannitrapani L, Alessandri A, Rappa F, Vuturo O, Montalto G.
    Liver Int; 2006 Nov; 26(9):1119-25. PubMed ID: 17032413
    [Abstract] [Full Text] [Related]

  • 25. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA, Miller C, Aucejo F, Lopez R, Quinn MK, Zein NN.
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Clinical presentation, outcome, and response to therapy among patients with acute exacerbation of chronic hepatitis C.
    Sagnelli E, Pisaturo M, Stanzione M, Messina V, Alessio L, Sagnelli C, Starace M, Pasquale G, Coppola N.
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1174-1180.e11. PubMed ID: 23591280
    [Abstract] [Full Text] [Related]

  • 28. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics.
    Tekin F, Gunsar F, Karasu Z, Akarca U, Ersoz G.
    Aliment Pharmacol Ther; 2008 Jun 01; 27(11):1081-5. PubMed ID: 18346186
    [Abstract] [Full Text] [Related]

  • 29. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.
    J Med Virol; 2007 Nov 01; 79(11):1686-95. PubMed ID: 17854035
    [Abstract] [Full Text] [Related]

  • 30. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation.
    Fernández I, Meneu JC, Colina F, García I, Muñoz R, Castellano G, Fuertes A, Abradelo M, Lumbreras C, Moreno E, Solís-Herruzo JA.
    Liver Transpl; 2006 Dec 01; 12(12):1805-12. PubMed ID: 17133585
    [Abstract] [Full Text] [Related]

  • 31. Pegylated interferon alfa-2a (40 kD) and ribavirin in haemodialysis patients with chronic hepatitis C.
    van Leusen R, Adang RP, de Vries RA, Cnossen TT, Konings CJ, Schalm SW, Tan AC.
    Nephrol Dial Transplant; 2008 Feb 01; 23(2):721-5. PubMed ID: 18042614
    [Abstract] [Full Text] [Related]

  • 32. [Dynamic changes in PD-1, TLR3, and TLR4 surface expression on peripheral blood mononuclear cells in chronic hepatitis C patients undergoing peg-IFNalpha-2a plus ribavirin combination therapy].
    Zhang M, Jiang YF, Xiao XQ, Liu SF, Peng ML, Liu D, Gong GZ.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 01; 21(3):196-201. PubMed ID: 23967741
    [Abstract] [Full Text] [Related]

  • 33. Treatment of hepatitis C virus genotype 3-infection.
    Pol S, Vallet-Pichard A, Corouge M.
    Liver Int; 2014 Feb 01; 34 Suppl 1():18-23. PubMed ID: 24373074
    [Abstract] [Full Text] [Related]

  • 34. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response.
    Fernández-Rodríguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincón D, Rodriguez-Caravaca G, Bárcena R, Serra MA, Romero-Gómez M, Fernandez I, Garcia-Samaniego J, Fuente J, Solá R, Moreno-Otero R, Planas R, Group for the Assessment of Prevention of Cirrhosis Complications and Virological Response (APREVIR).
    Am J Gastroenterol; 2010 Oct 01; 105(10):2164-72; quiz 2173. PubMed ID: 20700116
    [Abstract] [Full Text] [Related]

  • 35. Anti-Golgi complex antibodies during pegylated-interferon therapy for hepatitis C.
    Paraná R, Schinoni MI, de Freitas LA, Codes L, Cruz M, Andrade Z, Trepo C.
    Liver Int; 2006 Nov 01; 26(9):1148-54. PubMed ID: 17032416
    [Abstract] [Full Text] [Related]

  • 36. [Diagnosis, treatment, and follow-up of hepatitis C-virus related liver disease. Hungarian national consensus guideline].
    Hunyady B, Gervain J, Horváth G, Makara M, Pár A, Szalay F, Telegdy L, Tornai I.
    Orv Hetil; 2014 Mar 01; 155 Suppl():3-24. PubMed ID: 24631886
    [Abstract] [Full Text] [Related]

  • 37. PEG-interferon in acute and chronic hepatitis C: a review.
    Palumbo E.
    Am J Ther; 2009 Mar 01; 16(6):573-8. PubMed ID: 19433975
    [Abstract] [Full Text] [Related]

  • 38. Clinical trial results of peginterferons in combination with ribavirin.
    Craxi A, Licata A.
    Semin Liver Dis; 2003 Mar 01; 23 Suppl 1():35-46. PubMed ID: 12934167
    [Abstract] [Full Text] [Related]

  • 39. Interleukin-10.rs1800896 and Interleukin-18.rs1946518 gene polymorphisms could not predict the outcome of hepatitis C virus infection in Egyptian patients treated with pegylated interferon plus ribavirin.
    Abdelraheem WM, Hassuna NA, Abuloyoun SM, Abdel Ghany HM, Rizk HA, Abdelwahab SF.
    Arch Virol; 2016 Sep 01; 161(9):2473-80. PubMed ID: 27352267
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 50.